Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
No open-market purchase by an insider of MetLife was filed in the last 90 days. The latest on record was on May 19, 2023.
How often do MetLife insiders buy and sell shares?
Since 2003, MetLife insiders reported 31 open-market purchases and 312 sales on Forms 4 and 5, with purchases in 11 different years, most recently 2023.
Who is selling MetLife stock?
In the last 90 days, 1 insider of MetLife (MET) reported 1 open-market sale worth $19.3M in total on SEC Form 4. The largest seller by value was Michel Khalaf, with $19.3M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade MET?
Yes. Members of Congress disclosed 1 trade in MetLife (MET) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent is from Sen. Alan Armstrong.
When does MetLife report its next results?
MetLife's next results are expected on Feb 2, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
Close of Nov 18, 2026, vs Nov 17 · end-of-day, not a live quote
MET price and disclosed activity
+32.4% (+$24.42) from Nov 18, 2025 to Nov 18, 2026 · adjusted daily closes
Adjusted close went from $75.37 on Nov 18, 2025 to $99.79 on Nov 18, 2026 (+32.4%). Disclosed in this range: 1 insider trade, 1 pre-arranged insider sale, 1 Congress trade, and 60 13F position changes for 4 quarters ending in it.
$60$70$80$90$110$99.79
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 3 trades in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Life & Health Insurance company based in New York City, New York.
Last 12 months
+32.4%
S&P 500 +10.6% over the same dates
Market value
$62.7B
Close of Nov 18, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +10.6% over the same dates. Prices adjusted for splits and dividends.
Short interest: 10.7M shares sold short (1.7% of shares outstanding), −0.1% vs the previous count, 3.4 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Latest results: quarter ending Sep 30, 2026
Revenue
$20.5B
+18.2% vs the same quarter a year earlier
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $19.8B, at Sep 30, 2026
Net income, last 12 months
$5.13B
Operating profit covers interest 6.1x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 4, 2026.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of MetLife reported 31 open-market purchases and 312 sales since 2003; purchases in 11 different years, most recently 2023.
Year
Bought
Sold
2026
—
$21M2×2 trades
2025
—
$2.09M1×1 trade
2024
—
$7.21M5×5 trades
2023
$8791×1 trade
$1.61M3×3 trades
2022
$8.9K1×1 trade
$11.4M8×8 trades
2021
—
$5.6M6×6 trades
2020
—
$877K2×2 trades
2019
—
$851K4×4 trades
2018
$712K2×2 trades
$6.03M2×2 trades
2017
$1.03M2×2 trades
$7.54M5×5 trades
2016
—
$10M25×25 trades
2015
$9591×1 trade
$6.27M32×32 trades
2014
—
$7.81M9×9 trades
2013
—
$3.84M11×11 trades
2012
—
$3.63M8×8 trades
2011
—
$13.2M42×42 trades
2010
$358K13×13 trades
$4.21M49×49 trades
2009
$309K1×1 trade
$307K6×6 trades
2008
$304K7×7 trades
$5.24M57×57 trades
2007
—
$38.9M35×35 trades
2005
$25K1×1 trade
—
2004
$119K1×1 trade
—
2003
$167K1×1 trade
—
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Risk factors in the annual report
Latest annual report filed Feb 19, 2026, compared with the one filed Feb 21, 2025. Read the filing
All 35 risk factor headings match the year before, give or take wording.
Legal proceedings (Item 3)
See Note 24 of the Notes to the Consolidated Financial Statements.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Feb 19, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
When insiders usually buy
Last results
Nov 4, 2026
Within the 30 days after it, until Dec 4, 2026
Next results, expected
Feb 2, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From MetLife's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know MetLife's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of MetLife filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 2 open-market sales (about $21M, in 2 filings, by 2 people). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 3 open-market sales (about $5.72M, in 3 filings). (MetLife on OQRO)
Congress. Members of Congress filed 1 disclosure on MetLife in the 12 months to Nov 19, 2026: 1 purchase and 0 sales, by 1 member. In the 12 months before that: 3 disclosures. The largest range: Sen. Alan Armstrong, $1,001 to $15,000, filed Jul 21, 2026.
Funds and stakes. Fund 13F filings recorded in the 12 months show 22 new or larger positions and 39 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings. 1 federal contract award to the company was recorded in the 12 months, with about $3.45M obligated so far. A contract amount is what the agency obligated, not revenue. 7 lobbying reports naming the company were posted in the 12 months, reporting about $1.53M.
Company reports, price and press. MetLife filed a Form 8-K on Nov 10, 2026 (Items 1.01, 2.03) that OQRO classes as: signed an important agreement, and took on new debt or obligations. MetLife filed a Form 8-K on Nov 4, 2026 (Items 2.02, 7.01, 8.01) that OQRO classes as: reported its results, and shared information with investors (and 1 more item).
Who holds it. 1,439 funds reported a stake in MetLife in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (10.7% of the value reported), Dodge & Cox (10.0% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (7.3% of the value reported).
Attention. The English Wikipedia article on MetLife was read about 291 times a day in the 7 days to Nov 18, 2026, against a usual 282 a day over the 90 days before. Reads measure attention, not buying or selling.
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of MetLife filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 2 open-market sales (about $21M, in 2 filings, by 2 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 3 open-market sales (about $5.72M, in 3 filings).
The largest sale: Michel Khalaf, President & CEO, about $19.3M, filed Nov 12, 2026.
Congress
Members of Congress filed 1 disclosure on MetLife in the 12 months to Nov 19, 2026: 1 purchase and 0 sales, by 1 member. In the 12 months before that: 3 disclosures.
The largest range: Sen. Alan Armstrong, $1,001 to $15,000, filed Jul 21, 2026.
Funds and stakes
Fund 13F filings recorded in the 12 months show 22 new or larger positions and 39 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings
1 federal contract award to the company was recorded in the 12 months, with about $3.45M obligated so far. A contract amount is what the agency obligated, not revenue.
7 lobbying reports naming the company were posted in the 12 months, reporting about $1.53M.
FINRA short interest for MET on the settlement date of Oct 30, 2026 was 10,747,491 shares (-0.11% on the previous report), about 3.43 days of average volume.
In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: Bridgewater Associates (increased, 83,176 shares); the largest that shrank: none on record. A 13F is a quarter-end snapshot with no trade date.
For fiscal 2025, the company's proxy statement reported total compensation of $22.4M for its principal executive officer, and an average of $7.96M for the other named executive officers.
People read MetLife's Wikipedia article about 290 times a day over the last week, close to the 280 on a usual day of the three months before.
Company reports, price and press
MetLife filed a Form 8-K on Nov 10, 2026 (Items 1.01, 2.03) that OQRO classes as: signed an important agreement, and took on new debt or obligations.
MetLife filed a Form 8-K on Nov 4, 2026 (Items 2.02, 7.01, 8.01) that OQRO classes as: reported its results, and shared information with investors (and 1 more item).
MetLife filed a Form 8-K on Feb 24, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On February 24, 2026, the Board of Directors (the 'Board') of MetLife, Inc. (the 'Company') increased the number of directors serving on the Board from eleven to thirteen, and elected Daniel S. Glaser and Michelle R. Seitz as dir..."
MET closed at $99.79 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $99.58 to $99.79, a change of +0.2%.
Who holds it
1,439 funds reported a stake in MetLife in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (10.7% of the value reported), Dodge & Cox (10.0% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (7.3% of the value reported).
Attention
The English Wikipedia article on MetLife was read about 291 times a day in the 7 days to Nov 18, 2026, against a usual 282 a day over the 90 days before. Reads measure attention, not buying or selling.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
May 14, 2026Busiest day: 2,000 views on Jul 19, 2026Nov 18, 2026
Views of the article MetLife, by people (Wikimedia leaves out known bots). More readers means more attention, from news, results or anything else; it does not say anyone bought or sold. Source: Wikimedia pageviews.
Short sale volume: 50.5% of the volume reported to FINRA over the last 20 trading days was marked short, close to its 1-year average of 50.9%. FINRA daily files, to Nov 18, 2026.
Fails to deliver: 72K shares (about $6.96M) were not delivered on time for settlement on Oct 7, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 38.5% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (22.2% on ATS, 16.3% with other brokers), close to its 26-week average of 39.9%. Weeks of Oct 5 to Oct 30, 2026.
Week of May 4ATSOther off-exchangeFull height = all shares tradedWeek of Oct 26
Largest ATS: UBS ATS (14.1%), INTELLIGENT CROSS LLC (13.1%), SIGMA X2 (8.0%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Since Nov 17, 2025, MET is up 32.1% and the index fund is up 9.7%: 22 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much MET moves
A usual day
±0.9%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
2.6%Average distance between the low and the high of a session, over the last 14.
Largest one-day fall
−5.1%Feb 27, 2026
Largest one-day rise
+4.4%Apr 8, 2026
Deepest fall of the year
−18.0%From the close of Dec 15, 2025 to Mar 27, 2026.
Days of 5% or more
1Out of 252 sessions, in either direction.
Beta 0.6(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).